- In two randomized clinical trials that evaluate pain control after common and bunionectomy, Journavx has shown statistically significant reductions in acute surgical pain over a 48 -hour period compared to placebo.
- Journavx showed security in 3 clinical trials, with no serious side effects. Small side effects included itching, muscle spasms, rash and elevated levels of creatine phosphocinase.
The last
Recently, two -phase tests, randomized, double blind, placebo -controlled, evaluated the efficacy and safety of Journavx in controlling acute surgical pain. In the first test that evaluates after pain as a soft tissue pain model, patients receiving Journavx had a 47% reduction in pain levels, compared to 31% in placebo patients and 43% in patients receiving hydrocodone/acetaminopen. In the second test for pain control after bunion removal, a bone pain model, Journavx achieved a 51% reduction in pain level, compared to 53% for hydrocodone/acetaminophen and 38% for placebo. In both studies, Journavx has achieved a statistically significant decrease in pain compared to placebo, but not compared to hydrocodone/acetaminophen.
Doctor’s perspective
Post -functional pain is a common challenge for patients and doctors. Providing safe but adequate pain control improves the results of patients, but it may be a challenge for healthcare providers to facilitate the restrictions of available pain drugs. In addition, at a normal level, the pain process involves a complex multi -path interaction that can further complicate management. Opioids are often used to treat severe acid pain, but because they reduce pain by acting in the brain, they carry risks such as suppression and addiction. Other pain medications for pain include acetaminophen or non -steroidal anti -inflammatory drugs. A non -opioid candidate offers a novel and possibly a better alternative to today’s care model than several areas, including not only the control of pain but also the reduction of side effects and opioid dependence.
Molecular goals
Journavx blocks naV1.8 sodium channels with a voltage in the regional nervous system, which includes all the nerves in the body outside the brain and spinal cord. Inhibiting this channel prevents the transfer of pain signals to the brain and is interpreted as pain. As an oral analgesic, Journavx can provide systemic pain control, but without the risk of opioid associated. Journavx is the first approved drug in this class to treat acute pain.
Company history
Vertex Pharmaceuticals is an American biopharmaceutical company known for its previous work that develops gene remedies and cystic fibrosis treatments. Vertex recently funded the two randomized control tests that evaluate the Journavx for acute pain relief, which led to the approval of the Journavx FDA. This is an important milestone for the top, as it is the first approval for a new pain in 25 years.
© 2024 2 Minute Medicine, Inc. With all right. No projects can be reproduced without expressing a written consent of 2 minutes Medicine, Inc. Question on license license here. No article should be interpreted as a medical advice and is not intended as such by the authors or by 2 minutes Medicine, Inc.
Arabic
Chinese (Simplified)
Dutch
English
French
German
Italian
Portuguese
Russian
Spanish
Turkish